PMID- 18316335
OWN - NLM
STAT- MEDLINE
DCOM- 20080508
LR  - 20211203
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 47
IP  - 4
DP  - 2008 Apr
TI  - Mouse model of dermal fibrosis induced by one-time injection of 
      bleomycin-poly(L-lactic acid) microspheres.
PG  - 454-7
LID - 10.1093/rheumatology/ken058 [doi]
AB  - OBJECTIVE: Animal models are useful tools to study various aspects of human 
      diseases. Bleomycin (BLM)-induced scleroderma mouse has been widely investigated 
      as an animal model of scleroderma. Repeated injections of BLM, either daily or 
      every other day, for 3-4 weeks are required to induce scleroderma in mice. 
      Poly(L-lactic acid) (PLA) is a biodegradable, biocompatible and bioabsorbable 
      device that has been widely investigated for controlled drug release. In this 
      study, we fabricated BLM-containing PLA microspheres and subcutaneously injected 
      them into C3H mice for only one time. METHODS: Treated skins were harvested at 
      days 7 and 21. Then, histological examination and collagen content measurement 
      assay were performed. The mRNA expression of alpha1(I) collagen (COL1A1), 
      monocyte chemoattractant protein-1 (MCP-1), TGF-beta(1) and connective tissue 
      growth factor (CTGF) were quantified by real-time PCR. RESULTS: Dermal fibrosis 
      was histologically observed at day 7 after injection and remained present at day 
      21. Tissue responses against BLM-PLA microspheres alone were mild. Soluble 
      collagen content and expression level of alpha1(I) collagen mRNA were 
      significantly elevated at day 21. Expression levels of MCP-1 mRNA and TGF-beta(1) 
      mRNA at day 7 and CTGF mRNA at day 21 were also elevated. CONCLUSION: The present 
      study demonstrated for the first time that one-time injection of BLM-PLA 
      microspheres can induce dermal fibrosis in C3H mice. BLM-PLA microspheres thus 
      offer a labour-saving, simple and powerful tool to establish an animal model of 
      BLM-induced dermal fibrosis.
FAU - Shibusawa, Y
AU  - Shibusawa Y
AD  - Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22 
      Showa-machi, Maebashi, Gunma, 371-8511, Japan. yshibusa@showa.gunma-u.ac.jp
FAU - Negishi, I
AU  - Negishi I
FAU - Tabata, Y
AU  - Tabata Y
FAU - Ishikawa, O
AU  - Ishikawa O
LA  - eng
PT  - Journal Article
DEP - 20080303
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (CCN2 protein, human)
RN  - 0 (CCN2 protein, mouse)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Collagen Type I)
RN  - 0 (Collagen Type I, alpha 1 Chain)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta)
RN  - 11056-06-7 (Bleomycin)
RN  - 139568-91-5 (Connective Tissue Growth Factor)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Animals
MH  - Bleomycin/*administration & dosage/toxicity
MH  - Chemokine CCL2/biosynthesis/genetics
MH  - Collagen/analysis
MH  - Collagen Type I/biosynthesis/genetics
MH  - Collagen Type I, alpha 1 Chain
MH  - Connective Tissue Growth Factor
MH  - Delayed-Action Preparations
MH  - *Disease Models, Animal
MH  - Female
MH  - Fibrosis/chemically induced/metabolism
MH  - Gene Expression
MH  - Immediate-Early Proteins/biosynthesis/genetics
MH  - Injections, Subcutaneous
MH  - Intercellular Signaling Peptides and Proteins/biosynthesis/genetics
MH  - Lactic Acid
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Microspheres
MH  - Polymerase Chain Reaction/methods
MH  - RNA, Messenger/genetics
MH  - Scleroderma, Systemic/*chemically induced/metabolism/pathology
MH  - Skin/metabolism/*pathology
MH  - Transforming Growth Factor beta/biosynthesis/genetics
EDAT- 2008/03/05 09:00
MHDA- 2008/05/09 09:00
CRDT- 2008/03/05 09:00
PHST- 2008/03/05 09:00 [pubmed]
PHST- 2008/05/09 09:00 [medline]
PHST- 2008/03/05 09:00 [entrez]
AID - ken058 [pii]
AID - 10.1093/rheumatology/ken058 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2008 Apr;47(4):454-7. doi: 10.1093/rheumatology/ken058. 
      Epub 2008 Mar 3.